• Unequivocal histologically or cytologically confirmed diagnosis of metastatic or locally advanced NSCLC not amenable to treatment with surgical resection or combined chemoradiation

• Disease progression during or after treatment with at least one prior systemic therapy but no more than three lines of prior systemic therapy in the advanced or metastatic setting

• Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

• Documentation of the presence of a KRAS G12C mutation

• Availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen in a paraffin block (preferred) or 10-15 (15 preferred) unstained, freshly cut, serial slides with an associated pathology report

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Life expectancy of \>= 12 weeks